CJJ300
CJJ300 is a transforming growth factor-β (TGF-β) inhibitor with an IC50 of 5.3 μM. CJJ300 inhibits TGF-β signaling by disrupting the formation of the TGF-β-TβR-I-TβR-II signaling complex[1].
Product Specifications
CAS Number
[1807631-83-9]
UNSPSC
12352005
Target
TGF-β Receptor
Type
Reference compound
Related Pathways
TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cjj300.html
Concentration
10mM
Purity
99.36
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=C(C(C)=C(C(C)=C1CNC2=CC=CC=C2)CNC3=CC=CC=C3)CNC4=CC=CC=C4
Molecular Formula
C30H33N3
Molecular Weight
435.60
References & Citations
[1]Han Wu, et al. The development of a novel transforming growth factor-β (TGF-β) inhibitor that disrupts ligand-receptor interactions. Eur J Med Chem. 2020 Mar 1;189:112042.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15320357 1 Vial
Lentiviral human LRRC4B shRNA (UAS) - Lentiviral human LRRC4B shRNA (UAS, iRFP) (25)
Ask
View Details 
sc-286989 100 mg
1- (2-hydroxynaphth-1-yl) -6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline
Ask
View Details 